Plain-English translation of NCT06082284 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This trial is testing a new, very sensitive blood test designed to detect abnormal proteins that signal early-stage blood cell cancer — a condition called monoclonal gammopathy. Researchers want to understand how common this hidden condition is among patients visiting the hospital for other reasons, and whether the new test can catch it before symptoms develop.
Blood cell cancers often develop silently without obvious symptoms, so patients are usually only diagnosed by chance when tested for unrelated reasons. This study exists to see how often the new, more sensitive test detects these early signs, which could help doctors catch the disease much earlier when treatment may be more effective.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will use a leftover blood sample from tests you may have already had at the hospital to perform the new sensitive blood test. There are no additional visits or procedures required — the study simply analyzes existing samples to look for abnormal proteins. The whole process is non-invasive and happens in the laboratory.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China
Enrollment target
~10,000 participants
Started
October 2023
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nianyi Zeng
Zhujiang Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.